Grant Award Details
Grant Application Details
- Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial.
Therapeutic Candidate or Device
Tumor stem cell-targeted immunotherapy.
Destruction of host tumor stem cells by adaptive humoral cellular immunity will eradicate the origin of melanoma which will extend patient survival.
Unmet Medical Need
There is no effective treatment for metastatic melanoma. This treatment is the only one to target tumor stem cells in melanoma patients.
Complete Phase 3 trial to support BLA approval.
Major Proposed Activities
- Assessment of clinical safety and efficacy of the therapeutic candidate.
- Manufacturing of tumor stem cell-targeted immunotherapy.
- Enrollment of metastatic melanoma patients in phase 3 clinical trial.